The initial public offering of Molbio Diagnostics is now open for subscription from August 10 to August 12, 2026, with a price band of ₹768–₹807 per share. While brokerage Anand Rathi has issued a 'subscribe' rating for long-term investors, the company faces risks related to high government revenue dependence and a premium valuation.
Molbio Diagnostics Ltd has officially opened its initial public offering (IPO) for public subscription today, August 10, 2026. The company is seeking to raise ₹939.70 crore through this issue, which comprises a fresh issue of shares worth ₹200 crore and an offer for sale of existing shares valued at ₹739.70 crore. The price band for the IPO has been set at ₹768 to ₹807 per equity share, with a minimum lot size of 18 shares for potential investors. The subscription window will remain open until August 12, 2026.
The company is primarily known for its 'Truenat' platform, a diagnostic system used to test for various diseases, including tuberculosis, COVID-19, and HIV. This technology is designed to be portable and battery-operated, allowing medical professionals to conduct rapid molecular tests in areas where laboratory access might be limited. The platform has received endorsements from the World Health Organization, particularly for its role in tuberculosis diagnosis.
Anand Rathi, a brokerage firm, has provided a 'Subscribe' recommendation for long-term investors. The rationale behind this view is the company's focus on a recurring revenue model. Once the diagnostic devices are installed, the company continues to earn money by selling the disposable testing chips needed to run each test. The brokerage also highlighted the company’s strong research foundation, noting that it holds patents in over 100 countries. Financially, the company has shown growth, reporting a net profit of ₹164.14 crore for the 2026 fiscal year, an increase from ₹138.58 crore in the previous year.
Despite the positive view from the brokerage, investors should be aware of several material risks. A significant concern is the company's reliance on government procurement and international aid agencies, which account for approximately 84% of its finished goods revenue. This high level of concentration means that changes in government health budgets or shifts in public health policies could directly impact the company’s earnings. Furthermore, about 70% of the company's revenue is tied to tuberculosis diagnostic kits, making the business highly sensitive to any changes in demand for that specific product.
Valuation is another factor to consider. At the upper end of the price band, the company is valued at roughly 56.7 times its earnings for the 2026 fiscal year. Some analysts suggest that this is a premium valuation, which may influence short-term price performance. The diagnostic sector is also highly competitive, requiring constant innovation to maintain market share. Those looking to participate in the IPO should track the company’s future ability to diversify its revenue beyond government contracts and its success in launching new diagnostic assays. The shares are tentatively scheduled to list on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) on August 17, 2026.